Browsing by Author "Van Cutsem, Eric"
Now showing items 1-20 of 20
-
A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer
Van Cutsem, Eric; GARRALDA, Elena; Tai, David; de Braud, Filippo Guglielmo Maria; Geva, Ravit; Elez, Elena ; Tabernero, Josep (Oxford University Press, 2023-03) -
Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe
Kroese, Tiuri E.; van Laarhoven, Hanneke; Schoppman, Sebastian F.; Deseyne, Pieter; Van Cutsem, Eric; Haustermans, Karin; Alsina Maqueda, Maria (Elsevier, 2023-05) -
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
Tabernero Caturla, Josep; Grothey, Axel; Van Cutsem, Eric; Yaeger, Rona; Wasan, Harpreet; Yoshino, Takayuki (American Society of Clinical Oncology, 2021-02-01) -
European expert panel consensus on the clinical management of BRAFV600E-mutant metastatic colorectal cancer
Martinelli, Erika; Arnold, Dirk; Cervantes, Andrés; Stintzing, Sebastian; Van Cutsem, Eric; Tabernero Caturla, Josep (Elsevier, 2023-04) -
FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements
Bekaii-Saab, Tanios S; Valle, Juan W; Van Cutsem, Eric; Rimassa, Lorenza; Furuse, Junji; Ioka, Tatsuya; Macarulla Mercadé, Teresa (Future Medicine, 2020-10) -
First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study
Van Cutsem, Eric; Danielewicz, I.; Saunders, M. P.; Pfeiffer, P.; Argilés Martinez, Guillem; Borg, Christophe (Springer Nature, 2022-06-01) -
Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib
Hammel, Pascal; Kindler, H. L.; Reni, M.; Van Cutsem, Eric; Macarulla Mercadé, Teresa; Hall, Michael J (Oxford University Press, 2019-12) -
Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study
Tempero, Margaret A.; Tabernero Caturla, Josep; Reni, Michele; Van Cutsem, Eric; Hendifar, Andrew E.; Macarulla Mercadé, Teresa; Oh, Do-Youn (Elsevier, 2021-05) -
KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma
Tabernero Caturla, Josep; Van Cutsem, Eric; Fuchs, Charles; Janjigian, Yelena; Bhagia, Pooja; Bang, Yung-Jue (Future Medicine, 2021-08) -
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Golan, Talia; Hammel, Pascal; Reni, Michele; Van Cutsem, Eric; Macarulla Mercadé, Teresa; Hall, Michael J (Massachusetts Medical Society, 2019-06-02) -
Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study
Tabernero Caturla, Josep; Velez, L; Trevino, T. L.; Grothey, Axel; Yaeger, Rona; Van Cutsem, Eric (Elsevier, 2021-12) -
MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer
Janjigian, Yelena; Van Cutsem, Eric; Muro, Kei; Al-Batran, Salah-Eddin; Hyung, Woo Jin; Tabernero Caturla, Josep; Wainberg, Zev (Future Medicine, 2022-06) -
Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials
Yoshino, T.; Cleary, J. M.; Van Cutsem, Eric; Mayer, Robert; Ohtsu, Atsushi; Shinozaki, E.; Argilés Martinez, Guillem (Elsevier, 2020-01) -
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164
Le, Dung T.; Kim, Tae Won; Van Cutsem, Eric; Geva, Ravit; Jäger, Dirk; Hara, Hiroki; Elez Fernandez, Mª Elena (American Society of Clinical Oncology, 2020-01-01) -
Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer
Van Cutsem, Eric; Hochster, Howard S.; Shitara, Kohei; Mayer, Robert; Ohtsu, Atsushi; Falcone, Alfredo; Tabernero Caturla, Josep (Elsevier, 2022-12) -
Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC
Kopetz, Scott; Grothey, Axel; Van Cutsem, Eric; Yaeger, Rona; Wasan, Harpreet; Tabernero Caturla, Josep; Yoshino, Takayuki (Elsevier, 2022-06) -
Quality of life with first-line pembrolizumab for PD-L1–positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study
Van Cutsem, Eric; Valderrama, A.; Fuchs, Charles; Shitara, Kohei; Janjigian, Yelena; Alsina Maqueda, Maria; Bang, Yung-Jue (Elsevier, 2021-08) -
Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma
Van Cutsem, Eric; Tempero, Margaret A.; Sigal, Darren; Fazio, Nicola; Macarulla Mercadé, Teresa; Oh, Do-Youn (American Society of Clinical Oncology, 2020-09-20) -
Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study
Van Cutsem, Eric; Danielewicz, I.; Saunders, M. P.; Pfeiffer, P.; Argilés Martinez, Guillem; Borg, Christophe (Elsevier, 2020-09) -
Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study
Tabernero Caturla, Josep; Shitara, Kohei; Zaanan, Aziz; Doi, Toshihiko; Lorenzen, S.; Van Cutsem, Eric; Alsina Maqueda, Maria (Elsevier, 2021-08)